Trials / Withdrawn
WithdrawnNCT05611372
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline | 1 mg rasagiline |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2022-11-10
- Last updated
- 2025-01-07
Source: ClinicalTrials.gov record NCT05611372. Inclusion in this directory is not an endorsement.